Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Rezivertinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Rezivertinib is a once-a-day capsule for advanced non-small cell lung cancer (NSCLC) with an EGFR mutation. It was discovered and developed by Beta Pharma (Shanghai), which sells it in China as 瑞必达® (Ruibida). It is a third-generation EGFR medicine, built to work both on the usual EGFR mutations and on T790M, the change that commonly makes older EGFR treatment stop working.
China's National Medical Products Administration (NMPA) approved it on 20 May 2024, and a first-line use followed in late 2024. It is approved for adults with locally advanced or metastatic NSCLC who have:
It is a prescription cancer medicine and should only be used under a medical oncologist, after an EGFR mutation test.
In EGFR-mutated lung cancer, a growth signal on the cancer cells is switched on all the time. Rezivertinib binds to the faulty EGFR protein and blocks it for good (an irreversible inhibitor), cutting off that signal. NMPA describes it as acting on EGFR mutants such as T790M and L858R. The company reports that it crosses into the brain well, which matters because lung cancer often spreads there.
First treatment (REZOR): this double-blind phase 3 trial, published in The Lancet Respiratory Medicine in 2025, included 369 patients at 50 hospitals in China. The cancer was kept under control for a median of 19.3 months with rezivertinib against 9.6 months with a first-generation EGFR comparison medicine, a 52% lower risk of progression (hazard ratio 0.48). Overall survival data were still immature at the time of publication.
After earlier EGFR treatment (T790M): in the phase 2b study of 226 patients, 64.6% responded, the disease was controlled in 89.8%, and the median time before progression was 12.2 months. Median overall survival was 23.9 months. In the 29 patients with measurable brain tumours, 69.0% saw those tumours shrink.
The capsules come in a 30 mg strength. In the clinical trials the dose was:
Your oncologist will confirm the exact dose from the Chinese prescribing information.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood counts: the most common treatment-related side effects in the first-line trial were drops in white blood cells (40%), platelets (33%), red cells or anaemia (26%) and neutrophils (26%). Most were mild; severe drops were seen in only a few per cent of patients. Regular blood tests are part of treatment, and the dose can be paused or lowered if counts fall.
After earlier EGFR treatment: in the phase 2b study, 83.2% of patients had at least one drug-related side effect, most often low white cells (27.9%), low platelets (23.0%) and anaemia (22.6%), and no interstitial lung disease was reported. Always give your doctor a full list of the medicines and supplements you take.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Other EGFR lung cancer medicines we can import are covered on our Lazcluze and Zegfrovy pages.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each bottle holds 30 capsules of 30 mg. At the trial dose of 180 mg a day, one bottle lasts five days, so a month of treatment needs about six bottles, and we plan orders so supplies do not run short. The capsules travel in their sealed original bottles and are kept as directed on the pack, under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.
Patients treated at Delhi's cancer hospitals can receive their capsules quickly from our New Delhi dispatch point.
Bottles are sent to the patient or the hospital pharmacy, with import and batch papers included.
The treating oncologist can request it for a named patient, and we share the quote before ordering.
We plan refills ahead for patients in Chennai, since the daily dose uses several capsules.
Shipments are timed so a new supply arrives before the current bottles run out.
Patients in Kolkata and the north-east can get sealed original packs delivered to their door or hospital.
The documented import route works the same way in Pune, with updates along the way.
Send us the prescription and the EGFR mutation report to begin the request.
Supplies can go directly to hospitals in Vellore for patients under treatment there.
We serve patients from Punjab, Haryana and Himachal Pradesh through Chandigarh.
Delivery is arranged to patients and cancer centres throughout Uttar Pradesh.
Patients from across Kerala can receive their capsules in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
